Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content
  • Unicoat™ technology: Uniform Coating with Micro-crystals
    • A solution of excipient, paclitaxel and solvent are coated uniformly onto the balloon.2
    • Once the solvent dries, a uniform coating of paclitaxel micro-crystals and excipient remains on the balloon.2
    • Paclitaxel micro-crystals provide a large surface area, facilitating drug transfer to the lesion.3

       
  • Thanks to Unicoat™ technology,
    • In animal studies, the Kanshas™ DCB has been shown to have a higher drug concentration in the tissue than do other products at 30 and 45 days.3
    • In animal studies, the Kanshas™ DCB maintained a 90 day tissue residenency of paclitaxel which is intended to limit neointimal proliferation. 3
  • With up to 200mm balloon lengths, you will need only 1 balloon to treat lesion up to 200mm.
  • Kanshas™ DCB's core wire design enhances wire support, allowing for excellent pushability with RX system.4
Read more Read less
​Balloon diameter ​4.0 – 7.0 mm
Balloon length ​40 – 200 mm ​
Nominal pressure ​​8 atm
​Rated burst pressure 14 atm (ᴓ 4.0-6.0 mm) , 10 atm (ᴓ 7.0 mm) ​
Compatible guidewire ​​0.018 in
​Catheter length 150 cm ​
Catheter design ​Rapid Exchange ​
Drug ​Paclitaxel ​
Drug dose ​3.2 µg/mm² ​
​Excipient L-Serine Ethyl Ester HCI ​

Please contact our sales representative for ordering information.

 

 

 

 

 

 

 

 

1 PCR2018_LBT_KANSHAS1
2 Data on file at MicroVention FD15-0005
3 Kanshas DCB data on file at MicroVention, TR-15-159, animal study report, n=40. The other products' data were derived from literature and presentations as below. The end points of the studies from the other products were 30 and 45 days respectively.

Saami K. et al. "Vascular, Downstream, and Pharmacokinetic Responses to Treatment with a Low Dose Drug-Coated Balloon in a Swine Femoral Artery Model". Catheterization and Cardiovascular Interventions83:132-140(2014).

Robert J. Melder et al. "IN.PACTDEB technology and Pre-clinical Science". Presented at Leipzig Interventional Course(2013).

Carlos A. Gongora, et al. "Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing". JACC CardiovascularInterventions; 8(8):1115-23(2015).

Dorothea I. Axel, et al. "Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug Delivery". Circulation. 1997;96:636-645

4 Data on file at MicroVention FD15-0005

Did you not find the product you were looking for?